COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING PATIENTS WITH CANCER

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1), a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof and the use of the combination therapies for the treatment cancer.

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Marinello, Patricia, Perini, Rodolfo Fleury, Healy, Jane Anne, Jha, Sujata Shrawankuma, Willemann Rogerio, Jaqueline
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	Marinello, Patricia Perini, Rodolfo Fleury Healy, Jane Anne Jha, Sujata Shrawankuma Willemann Rogerio, Jaqueline
description	The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1), a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof and the use of the combination therapies for the treatment cancer.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2024010729A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2024010729A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2024010729A13</originalsourceid><addsrcrecordid>eNqNjcEKgkAURd20iOofHrQW1IJo-RyfOjDOyPgsXInEtIoS7G_62cZo16bVvVzO4S6DlzBVKjWyNBq4JIt1ByYHhDoLY0DNWBgtG_Y1A4XF7mcjffK6likYO3sl2goFtSwFKtUBCkE1Y6oIGlT8eSF_kXucLc1uAbUP0tzAWXIJArUguw4W1-E2uc03V8E2JxZl6MZH76ZxuLi7e_Ztk0TJPoqjQ3LEePcf9Qat40PR</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING PATIENTS WITH CANCER</title><source>esp@cenet</source><creator>Marinello, Patricia ; Perini, Rodolfo Fleury ; Healy, Jane Anne ; Jha, Sujata Shrawankuma ; Willemann Rogerio, Jaqueline</creator><creatorcontrib>Marinello, Patricia ; Perini, Rodolfo Fleury ; Healy, Jane Anne ; Jha, Sujata Shrawankuma ; Willemann Rogerio, Jaqueline</creatorcontrib><description>The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1), a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof and the use of the combination therapies for the treatment cancer.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240111&DB=EPODOC&CC=US&NR=2024010729A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76419</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240111&DB=EPODOC&CC=US&NR=2024010729A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Marinello, Patricia</creatorcontrib><creatorcontrib>Perini, Rodolfo Fleury</creatorcontrib><creatorcontrib>Healy, Jane Anne</creatorcontrib><creatorcontrib>Jha, Sujata Shrawankuma</creatorcontrib><creatorcontrib>Willemann Rogerio, Jaqueline</creatorcontrib><title>COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING PATIENTS WITH CANCER</title><description>The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1), a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof and the use of the combination therapies for the treatment cancer.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjcEKgkAURd20iOofHrQW1IJo-RyfOjDOyPgsXInEtIoS7G_62cZo16bVvVzO4S6DlzBVKjWyNBq4JIt1ByYHhDoLY0DNWBgtG_Y1A4XF7mcjffK6likYO3sl2goFtSwFKtUBCkE1Y6oIGlT8eSF_kXucLc1uAbUP0tzAWXIJArUguw4W1-E2uc03V8E2JxZl6MZH76ZxuLi7e_Ztk0TJPoqjQ3LEePcf9Qat40PR</recordid><startdate>20240111</startdate><enddate>20240111</enddate><creator>Marinello, Patricia</creator><creator>Perini, Rodolfo Fleury</creator><creator>Healy, Jane Anne</creator><creator>Jha, Sujata Shrawankuma</creator><creator>Willemann Rogerio, Jaqueline</creator><scope>EVB</scope></search><sort><creationdate>20240111</creationdate><title>COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING PATIENTS WITH CANCER</title><author>Marinello, Patricia ; Perini, Rodolfo Fleury ; Healy, Jane Anne ; Jha, Sujata Shrawankuma ; Willemann Rogerio, Jaqueline</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2024010729A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>Marinello, Patricia</creatorcontrib><creatorcontrib>Perini, Rodolfo Fleury</creatorcontrib><creatorcontrib>Healy, Jane Anne</creatorcontrib><creatorcontrib>Jha, Sujata Shrawankuma</creatorcontrib><creatorcontrib>Willemann Rogerio, Jaqueline</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Marinello, Patricia</au><au>Perini, Rodolfo Fleury</au><au>Healy, Jane Anne</au><au>Jha, Sujata Shrawankuma</au><au>Willemann Rogerio, Jaqueline</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING PATIENTS WITH CANCER</title><date>2024-01-11</date><risdate>2024</risdate><abstract>The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1), a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof and the use of the combination therapies for the treatment cancer.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_US2024010729A1
source	esp@cenet
subjects	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING PATIENTS WITH CANCER
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A47%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Marinello,%20Patricia&rft.date=2024-01-11&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2024010729A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true